… cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF,
we found that dapagliflozin … in patients with and without HFrEF and reduced cardiovascular …

… Dapagliflozin in patients with heart failure and … of dapagliflozin in patients with heart failure
and reduced ejection fraction consistent in patients with and without type 2 diabetes mellitus? …

… 2 diabetes mellitus (T2DM) is a major cause of heart failure (… (HFpEF), as well as cardiovascular
disease [1, 2]. Sodium … of dapagliflozin on the LV diastolic function of T2DM patients …

… Data for patients randomized to dapagliflozin 10 mg or placebo with a history of HF were
pooled from … Type 2 diabetes mellitus (T2DM) is a growing epidemic with a marked impact on …

… Type 2 diabetes mellitus (T2DM) and heart failure (HF) commonly coexist and can be lethal
(1). … class of diabetes therapy that reduces HF hospitalization and cardiovascular (CV) death. …

… that treatment with dapagliflozin of T2DM patients who had or were at risk for atherosclerotic
cardiovascular disease, did not result in a higher or lower rate of cardiovascular events than …

… worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group
and in 326 patients (… Death from cardiovascular causes occurred in 227 patients (9.6%) in the …

… and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores
the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes …

… of type 2 diabetes mellitus, reduce the risk of death and other adverse outcomes among
patients with chronic heart failure and a reduced ejection fraction (ie, a left ventricular ejection …

… the risk of HF hospitalization in patients with type 2 diabetes mellitus, including those with
CKD (8-12). … to patients with CKD without type 2 diabetes in the DAPA-CKD (Dapagliflozin and …